Journal article
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Abstract
BACKGROUND: Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because most biliary tract cancers have an immune-suppressed microenvironment, immune checkpoint inhibitor monotherapy is associated with a low …
Authors
Kelley RK; Ueno M; Yoo C; Finn RS; Furuse J; Ren Z; Yau T; Klümpen H-J; Chan SL; Ozaka M
Journal
The Lancet, Vol. 401, No. 10391, pp. 1853–1865
Publisher
Elsevier
Publication Date
6 2023
DOI
10.1016/s0140-6736(23)00727-4
ISSN
0140-6736